- Home
- NCPL vs SCNX Comparison
NCPL vs SCNX Comparison
Compare NCPL & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | SCNX |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Other Pharmaceuticals |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 16.2M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NCPL | SCNX |
|---|---|---|
| Price | $1.44 | $3.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.1M | 44.7K |
| Earning Date | 12-14-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $869,460.00 | ★ $3,831,778.00 |
| Revenue This Year | N/A | $743.36 |
| Revenue Next Year | N/A | $325.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.21 | $2.64 |
| 52 Week High | $2.66 | $106.25 |
Technical Indicators
Market Signals| Indicator | NCPL | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 47.30 |
| Support Level | $0.43 | $2.64 |
| Resistance Level | $1.87 | $10.60 |
| Average True Range (ATR) | 0.47 | 0.28 |
| MACD | -0.05 | 0.12 |
| Stochastic Oscillator | 31.87 | 77.88 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.